← Back to Clinical Trials
Recruiting NCT07476690

NCT07476690 Effect of rESWT Session Frequency on Spasticity and Function Assessed by Sonoelastography in Children With Cerebral Palsy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07476690
Status Recruiting
Phase
Sponsor Sisli Hamidiye Etfal Training and Research Hospital
Condition Cerebral Palsy (CP)
Study Type INTERVENTIONAL
Enrollment 45 participants
Start Date 2025-11-15
Primary Completion 2026-03-01

Trial Parameters

Condition Cerebral Palsy (CP)
Sponsor Sisli Hamidiye Etfal Training and Research Hospital
Study Type INTERVENTIONAL
Phase N/A
Enrollment 45
Sex ALL
Min Age 6 Years
Max Age 14 Years
Start Date 2025-11-15
Completion 2026-03-01
Interventions
Real radial extracorporeal shock wave therapy (rESWT)Sham radial extracorporeal shock wave therapy (rESWT)Conventional physical therapy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Spasticity is a major contributor to functional limitations in children with cerebral palsy. Radial extracorporeal shock wave therapy (rESWT) has emerged as a non-invasive method for reducing spasticity; however, the optimal session frequency remains unclear. This randomized, assessor-blinded, parallel-group controlled trial investigates the effects of different rESWT session frequencies on spasticity, motor function, balance, pain, and muscle properties in children with cerebral palsy. Participants are randomly assigned to three groups receiving sham rESWT, one real rESWT session per week combined with sham, or two real rESWT sessions per week, in addition to routine neurological rehabilitation. Outcomes are assessed using clinical scales and ultrasonography-based measures, including shear wave elastography. The study aims to define the dose-response relationship of rESWT and inform optimal treatment protocols in pediatric neurorehabilitation.

Eligibility Criteria

Inclusion Criteria: * Children aged 6-14 years diagnosed with cerebral palsy according to the Rosenbaum diagnostic criteria. * Gross Motor Function Classification System (GMFCS) level I, II, or III. * Modified Ashworth Scale (MAS) score \>1 and ≤3 in unilateral or bilateral ankle plantar flexor muscle groups. * Presence of a spastic gait pattern characterized by a dynamic component of ankle equinus. Exclusion Criteria: * Age younger than 6 years or older than 14 years. * Botulinum toxin type A injection or extracorporeal shock wave therapy (ESWT) within 6 months prior to enrollment. * Fixed contracture with passive joint range of motion (ROM) \<5° in the affected extremity, or significant bone or joint deformity. * History of orthopedic surgery (tendon release or transfer, tenotomy, muscle release surgery, arthrodesis) involving the affected extremity. * Cognitive or behavioral disorders that would prevent participation in the intervention or assessments. * Uncontrolled systemic diseas

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology